HLB Life Science Co. Ltd (067630) — Cash Flow Reinvestment Rate
HLB Life Science Co. Ltd (067630) has a Cash Flow Reinvestment Rate of 2.19x as of March 2023, reinvesting ₩7.79 Billion (capex ₩3.52 Billion plus investments ₩-4.27 Billion) from operating cash flow of ₩3.55 Billion. See HLB Life Science Co. Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
HLB Life Science Co. Ltd Cash Flow Reinvestment Rate (2012–2020)
Historical reinvestment intensity for HLB Life Science Co. Ltd across 4 annual periods. For the full cash flow conversion analysis, see HLB Life Science Co. Ltd (067630) cash flow conversion.
Annual Cash Flow Reinvestment Rate for HLB Life Science Co. Ltd (2012–2020)
Year-by-year capital reinvestment analysis for HLB Life Science Co. Ltd. See 067630 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 12.05x | ₩24.21 Billion | ₩2.01 Billion | ₩8.41 Billion | ▲ +9080.6% |
| 2014 | 0.13x | ₩1.37 Billion | ₩10.43 Billion | ₩236.21 Million | ▲ +651.5% |
| 2013 | 0.02x | ₩51.48 Million | ₩2.95 Billion | ₩51.48 Million | ▼ -97.3% |
| 2012 | 0.66x | ₩9.18 Billion | ₩13.97 Billion | ₩9.18 Billion | — |